Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Financial Performance - Intellia Therapeutics reported a quarterly loss of $1.24 per share, which is better than the Zacks Consensus Estimate of a loss of $1.32, and an improvement from a loss of $1.46 per share a year ago, representing an earnings surprise of 6.06% [1] - The company posted revenues of $12.87 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 45.95%, compared to revenues of -$1.92 million in the same quarter last year [2] Market Performance - Intellia Therapeutics shares have declined approximately 7.4% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's current consensus EPS estimate for the upcoming quarter is -$1.34 on revenues of $10.38 million, and for the current fiscal year, it is -$5.01 on revenues of $70.22 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Intellia Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]